Can a patient start treatment on one JAK2 inhibitor and later switch to a different JAK2 inhibitor? Why would this be done?
The answer is, scientifically, we're still trying to figure out a lot of those questions. We do know that sequencing JAK2 inhibitors is a very important question.
And already the label for fedratinib is for patients that had already experienced ruxolitinib. So that's one indication for switching from one JAK2 inhibitor to the other.
If frontline therapies such as ruxolitinib were ineffective, suboptimal, or patients were experiencing toxicities from the ruxolitinib, then that's a reason to switch with fedratinib being the point JAK2 inhibitor to make that change.
The other considerations in clinical practice are that, as I mentioned, the other JAK2 inhibitors have a very niche label and subpopulation of patients where they can be very effective.
So in my clinical practice, I may have a patient that I start with ruxolitinib. But if they were to develop some type of issue with their platelets, I may reach for pacritinib. If they were to have some issue with their hemoglobin, I may reach for momelotinib.
So we have the armamentarium to mix and match the JAK2 inhibitors, depending on the clinical situation that we're working in real time for the patient.
HealthTree • October 17, 2025